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Background: Neo-adjuvant hormone therapy (NHT) following radical prostatectomy (RP) or radiotherapy has been
utilized in the multimodal approach to patients with intermediate- to high-risk prostate cancer (PCa). Herein, we
performed a systematic review and meta-analysis of published randomized trials to evaluate the clinical efficacy of
NHT.
Methods: Literatures were searched from PubMed, EMBASE, Web of Science, and Cochrane Library for comparing
neo-adjuvant therapy group (NHT plus radiotherapy or radical prostatectomy) with traditional therapy (radiotherapy
or prostatectomy) alone. Quality of the research was assessed on the basis of the Cochrane’s risk of bias of randomized
controlled trial. Comparable information were obtained from eligible trials and assembled for meta-analysis up to 31
August 2014. RevMan 5.2 software was used for statistical analysis.
Results: Fifteen randomized controlled trials (RCTs) (total 5,194 patients) were included in this study. Meta-analysis
showed there was a significant improvement in overall survival (OS) (Odds ratio (OR) = 1.51, 95% confidence interval
(CI) 1.22 to 1.87, P = 0.0002), positive surgical margin (PSM) rate (OR = 0.30, 95% CI 0.24 to 0.38, P < 0.00001), and
biochemical disease-free survival (bDFS) (OR = 1.95, 95% CI 1.13 to 3.39, P = 0.02), but no significant difference in
disease-free survival (OR = 1.52, 95% CI 0.90 to 2.59, P = 0.12) and clinical disease-free survival (cDFS) (OR = 0.96,
95% CI 0.22 to 4.18, P = 0.95). Heterogeneity and risk of bias were observed between different studies.
Conclusions: Patients with aggressive prostate cancer would better benefit from the receipt of neo-adjuvant
therapy. Physicians should make individualized treatment strategies according to adverse reactions, financial
capacities, and personal wishes.
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Currently, prostate cancer (PCa) is considered to be one
of the most common cancers in Western countries [1].
With the widespread use of prostate-specific antigen
(PSA) screening and the development of imaging tech-
nology, PCa incidence rates have been increasing rapidly
in Asian countries, especially, in developed metropolitan
areas [2]. Radical radiotherapy (RT) or radical prostatec-
tomy (RP) integrated with neo-adjuvant hormone ther-
apy (NHT) has been utilized in multimodal treatment in
patients with intermediate- to high-risk PCa.* Correspondence: haowenj73@126.com
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unless otherwise stated.One of the reasons why NHT is recommended for pa-
tients in all risk groups is that it can shrink prostate vol-
ume before RT or RP, thereby reducing the radiation
dose to critical organs or tissue injury during operation
and leading to a safer and more thorough treatment [3].
NHT plus RT or RP was found to have better efficacy
than traditional therapy (radiotherapy or surgery alone)
in some randomized controlled trials (RCTs), especially,
in patients with intermediate- or high-risk PCa [4-6].
In trials of NHT prior to RT, specific indicators such
as overall survival (OS), distant metastasis, biochemical
disease-free survival (bDFS), and biochemical failures is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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[7,8]. In patients receiving NHT before RP, pathological
down-staging and positive surgical margin (PSM) rates
were obviously improved in certain trials [9], but this
did not lead to an improvement in OS and disease-free
survival (DFS) [10,11].
The purpose of the present study was to determine
treatment efficacy in patients who had received NHT
prior to RT or RP (which is considered the first-line
treatment for PCa), by performing a systematic review
and meta-analysis of RCTs in men with non-metastatic
PCa. In this way, we aimed to conclusively establish




This study does not involve human subjects and does
not require Institutional Review Board review or con-
sent. Articles were gathered by searching the following
databases: PubMed, EMBASE, Web of Science, and
Cochrane Library. In addition, abstracts and presenta-
tions were collected through major academic confer-
ences, such as American Society of Clinical OncologyFigure 1 Flow diagram illustrated the process of the study selection f(ASCO), European Society for Medical Oncology (ESMO),
and Federation of European Cancer (FEC). Furthermore,
we searched the reference lists of reviews and RCTs to
find potentially eligible literature. The deadline for the
literature search was 31 August 2014.
We used the following MeSH terms integrated with
free terms in all the search strategies: prostate cancer,
neo-adjuvant hormone therapy, radiotherapy, prostatec-
tomy, review, meta-analysis, systematic review, random-
ized, phase III. Only articles published in English were
selected. When the study outcomes were inexplicit or
more details were required, we contacted the corre-
sponding author to obtain the original data.Trial identification criteria
The inclusion criteria, based on the PICO principles, are
as outlined below.
(1) Participants (P): All patients who were diagnosed
with non-metastatic PCa on cytological and patho-
logical examination were eligible to be recruited to this
systematic review. The nationality and race were not re-
stricted. None of the patients had any severe concomi-
tant disease.or the meta-analysis.
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analyzed neo-adjuvant therapy (NHT prior to RT or RP)
versus traditional therapy (RT or RP alone) in non-
metastatic PCa patients, in order to compare the clinical
results, including efficacy and safety, between two the
groups were eligible.
(3) Outcomes (O): We included studies that compared
the indicators OS, PSM, and DFS rates between the
NHT plus RP group and the RP only group; and OS,
bDFS, and clinical disease-free survival (cDFS) rates be-
tween the NHT plus RT group versus the RT only
group.
We excluded articles if (1) the study design was not a
RCT (for example, retrospective study, cohort study, and
case reports), (2) the study was not an original article
(for example, letters, reviews), and (3) the therapeutic
effect was insufficient to obtain useful information.Table 1 Pretreatment characteristics of patients included in s
Author Sample size
(ntg/ttg)
Age (years) (ntg/ttg) PSA level (ng
Pilepich 2001 [12] 226/230 No record No record
Laverdiere 2004 [13] 149/154 Median: 69/68 Median: 9.3/12
Soloway 1995 [14] 149/154 Mean:
64.9 ± 5.7/65.4 ± 5.9
Median: 14.3/1
Denham 2005 [15] 270, 272/276 Median: 68, 68/67 Median: 14.4, 1
Roach 2008 [5] 224/232 Median: 70/71 Median: 22.6/3
Deham 2011 [6] 265, 267/270 Median: 68, 68/67 Median: 14.4, 1
Dalkin 1996 [16] 30/31 Median: 65.5/64.7 4.1 to 10 (16/1
20 (9/9), >20 (
Goldenberg 1996 [17] 112/101 Mean:
62.5 ± 6.0/62.2 ± 5.9
0 to 4 (10/13),
10 (45/41), 10.1
25.1 to 50 (13/
Labrie 1997 [18] 71/90 Range: 46 to 72 ≤10 (67/53), >
Schulman 2000 [9] 192/210 No record No record
Selli 2002 [19] 143, 122/128 Mean:
65.43, 66.16/65.72
Median: 10.15,
Soloway 2002 [20] 149/154 Mean: 64.9/65.4 Median: 14.3/1
Aus 2002 [21] 63/63 Mean: 67/66 Median: 12.0/1
Klotz 2003 [10] 112/101 Median: 64/63 <10 (61/54), 10
20 (32/26), >20
Prezioso 2004 [22] 91/93 Mean: 64.9/64.5 <4 (ntg:6), ≥4
≥10 (ntg: 39)
Ntg/ttg, neo-adjuvant therapy group/traditional therapy group; PSA, prostate-specifData extraction
The information extracted from each study included
the following: first author’s name, time of publication,
patient characteristics, sample size, and outcomes. Data
extraction was independently performed by three inves-
tigators (Hu, Xu, and Zhu). Two of the investigators (Hu
and Xu) evaluated the quality of the original research by
means of the Cochrane Collaboration quality checklist
for RCTs, and disagreements between them were re-
solved by consensus.Data analysis
Survival rate was used as a binary variable in all the in-
cluded studies. Therefore, the log of the odds ratio (OR)
and the 95% confidence interval (CI) were reckoned as
the effect size for each considered endpoint.ystematic review
/ml) (ntg/ttg) Clinical stage (ntg/ttg) Gleason score (ntg/ttg)
T2 to 4 2 to 6 (total: 129),
7 (total: 176),




7 to 10 (total: 77)
2.5 T2b, NxM0 Mean: 6.1 ± 0.17/5.8 ± 0.16
4.6/16.4 T2b (66, 68/72),
T2c (88, 94/92),
T3 to 4 (111, 105/106)
2 to 6 (117, 122/113),
7 (92, 99/114),
8 to 10 (53, 43/41)
3.8 T2 to 4 3 to 6 (70/59),
7 to 10 (145/156)
4.5/16.4 T2b (67, 68/72),
T2c (87, 94/92),
T3 to 4 (111, 105/106)
2 to 6 (118, 123/114),
7 (94, 101/115),
8 to 10 (53, 43/41)
8), 10.1 to
3/1)
T1c (17/16), T2a (8/12),
T2b (3/0)
2 to 4 (8/6), 5 to 7 (16/21),




T1b (5/4), T1c (5/3),
T2a (30/33), T2b (19/17),
T2c (42/34)
2 to 4 (2/5), 5 to 7 (82/75),
8 to 10 (15/11)
10 (23/18) B0 (3/3), B1 (43/39),
B2 (29/17), C1 (8/7), C2 (7/5)
No record
T2 (105/115), T3 (87/95) No record
10.0/10.20 T2 to 3, N0, M0 2 to 6 (29,2/46), 7 (31,8/1),
8 to 10 (0,11/0)
2.5 T2b Mean: 6.1/5.8
1.2 T1b to T1c (10/15),
T2a (10/10), T2b to
T3a (43/38)
2 to 4 (2/1), 5 to 6(26/22),
7 to 10 (35/40)
to
(17/18)
T1b to T1c (12/7),
T2a (36/35), T2b (19/21),
T2c (41/32)
2 to 6 (75/73), 7(21/17),
8 to 10 (14/8)
< 10 (ntg: 30), T1a to T2b No record
ic antigen.
Table 2 Characteristics of agent trials included in systematic review




Tumor size was measured by the surface area
palpable by rectal examination. Performance
score (KPS) = 60 positive lymph nodes if below
the common iliac level
Patients with involved common
peri-aortic or iliac lymph node
2 months goserelin acetate ((3.6 mg
every 4 weeks) flutamide (250 mg tid)
NHT followed by RT and continued
during RT versus RT alone. Pelvis: 44






Age <75 years, PSA <50 mg/ml, without bone
metastases
No previous hormonal therapy or
chemotherapy
3 months leuprolide (7.5 mg monthly)
flutamide (250 mg tid)
NHT followed by RT versus RT alone.





Age <75 years, PSA <50 ng/ml, normal bone
scan
No previous hormonal therapy or
chemotherapy
2 weeks leuprolide (7.5 mg monthly)
flutamide (250 mg tid)




No bone metastases, prostatic acid
phosphatase <1.8 u/ml, PSA <50 ng/ml
Renal dysfunction, hepatic disease,
other malignancies or concomitant
anti-androgenic medication
3 months cyproterone acetate (300 mg
daily for 12 weeks), 6 months
cyproterone acetate
3 or 6 months NHT followed by RT
versus RT alone. Prostate/seminal





bulky (5*5 cm) tumors, with or without pelvic
lymph node involvement
no follow-up data 2 months flutamide (250 mg tid),
goserelin (3.6 mg every 4 weeks)
NHT followed by RT versus RT alone.
Regional lymphatics: 44 to 46 Gy





Histologically confirmed, informed consent Significant intercurrent medical
conditions, prior malignancies or
metastases
Goserelin (3.6 mg given subcutaneously
every month), flutamide (250 mg tid)
3 or 6 months NHT followed by RT
versus RT alone. Prostate and seminal









Histologically confirmed, prostatic acid
phosphatase <1.8 u/ml, PSA <50 ng/ml
Renal dysfunction, hepatic disease,
other malignancies or concomitant
anti-androgenic medication
Cyproterone acetate (300 mg daily for
12 weeks)




Histologically confirmed, life expectancy
>10 years
No record 3 months flutamide and leuprolide
acetate




Histologically confirmed, PSA <100 ng/ml No record 3 months goserelin (3.6 mg
subcutaneously depot injection each
month) flutamide (250 mg tid)




Histologically confirmed, informed consent No record Goserelin (3.5 mg subcutaneously depot
injection each month) bicalutamide
(50 mg/day)






Age <75 years, PSA <50 ng/ml, normal
bone scan
No previous hormonal therapy or
chemotherapy
3 months leuprolide (7.5 mg monthly)
flutamide (250 mg tid)




Previously untreated, age <75 years, life
expectancy >10 years
Positive lymph nodes 3 months triptorelin (3.75 mg i.m.
monthly)




Histologically confirmed, prostatic acid
phosphatase <1.8 u/ml, PSA <50 ng/ml
Renal dysfunction, hepatic disease,
other malignancies or concomitant
anti-androgenic medication
3 months cyproterone acetate (300 mg
daily for 12 weeks)




Lifespan >5 years, WHO performance status
up to 2, no evidence of metastases, informed
consent
No previous hormonal therapy or
chemotherapy, no previous
orchidectomy or other malignancies
3 months leuprolide (3.75 mg)
cyproterone acetate (300 mg daily for
3 weeks)
NHT followed by RP versus RP alone Median:
unknown
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statistical heterogeneity across trials. If heterogeneity
was not present (P > 0.10, I2 < 50%), the fixed-effects
model would be selected for further analysis; otherwise,
the random-effects model would be adopted.
The OR and 95% CI results could be divided into the
following: (a) OR > 1 and 95% CI not containing 1, sur-
vival rate was significantly higher in the combined ther-
apy group than in the traditional therapy group; (b)
OR < 1 and 95% CI not containing 1, survival rate was
significantly higher in the traditional therapy group; (c)
OR = 1, no difference in the failure rates of the two
groups; and (d) 95% CI containing 1, statistically insig-
nificant difference in the failure rates of the two groups.
All statistical analyses were performed using RevMan
5.2 software.Results
Study selection outcomes and quality assessment
The search strategy identified 102 possible studies from
all the databases. After we eliminated studies according
to the exclusion criteria, 15 papers were considered rele-
vant to this review. The detailed literature screening
process has been presented in a flowchart (Figure 1).
A total of 5,194 PCa patients were included in this
study, 2,907 and 2,287 in the neo-adjuvant therapy
group and traditional therapy group, respectively. The
follow-up duration was not exactly the same in the
included studies, but in most studies, follow-up was per-
formed for at least 3.7 years. The pretreatment (baseline)
characteristics of the patients were similar in the two
groups (Table 1). The characteristics of each trial have
been summarized in Table 2.
Although all the included studies were RCTs, only
three mentioned the procedure of randomization. Two
were randomized mainly on the basis of phone calls
[10,16], and one was randomized by the minimization
technique after stratification [6]. Only one study men-
tioned the number and causes of dropouts and with-
drawals [13]. None of the trials described the procedures
used to evaluate the results or blind the allocation of
interventions.Figure 2 Meta-analysis of overall survival compared neo-adjuvant theOverall survival
Five studies evaluated OS in the neo-adjuvant therapy
group compared with the traditional therapy group.
Since no heterogeneity was found among these studies
(P = 0.49, I2 = 0%), a fixed-effects model was selected for
data analysis. The outcomes suggested that OS was sig-
nificantly longer in the neo-adjuvant therapy group than
in the traditional therapy group (OR = 1.51, 95% CI: 1.22
to 1.87, P = 0.0002; Figure 2).
Disease-specific survival was presented in two of the
above studies [9,21] and showed no obvious improve-
ment with neo-adjuvant therapy (relative risk = 1.00, 95%
CI: 0.98 to 1.03, P = 0.77).Positive surgical margin rate
Nine RCTs assessed the PSM rates. No obvious hetero-
geneity was observed between these studies (P = 0.18,
I2 = 30%), so a fixed-effects model was applied to analyze
the effect size. The PSM rate was significantly lower in
the neo-adjuvant therapy group than in the traditional
therapy group (OR = 0.30, 95% CI: 0.24 to 0.38, P <
0.00001; Figure 3).
Positive lymph node involvement was found in five tri-
als [9,10,16,20,22], and the outcome was less frequent in
the neo-adjuvant therapy group (relative risk = 0.66, 95%
CI: 0.47 to 0.94, P = 0.02).Disease-free survival
Six RCTs reported DFS rates, and significant heterogen-
eity was detected among them (P < 0.00001, I2 = 84%).
Hence, a random-effects model was chosen. There was no
significant difference between the neo-adjuvant therapy
group and the traditional therapy group in terms of DFS
(OR = 1.52, 95% CI: 0.90 to 2.59, P = 0.12; Figure 4).
One study [22] attempted to assess the efficacy of
NHT on PSA relapse and pathological variables in con-
trast with prostatectomy alone, and defined PSA relapse
based on the available data. However, the median follow-
up time (<7 months) was too short to meet the study re-
quirements, and thus, the information was regarded as
insufficient to accomplish the statistical analysis.rapy group versus traditional therapy group.
Figure 3 Meta-analysis of positive surgical margin rate compared neo-adjuvant therapy group versus traditional therapy group.
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Three RCTs examined bDFS rates. Due to apparent het-
erogeneity between two of these studies (P = 0.05, I2 =
66%), a random-effects model was adopted. In the neo-
adjuvant therapy group, bDFS was significantly increased
compared with that in the traditional therapy group
(OR = 1.95, 95% CI: 1.13 to 3.39, P = 0.02; Figure 5).
Specifically, Pilepich et al. [12] reported the 8-year
bDFS rates in the treatment (24%) and control arms
(10%, P < 0.0001). Laverdiere et al. [13] found that the 7-
year bDFS was significantly higher in the neo-adjuvant
treatment arm than in the control arm (P = 0.009). Den-
ham et al. [15] reported a significant improvement in
the 5-year bDFS in the neo-adjuvant therapy group (P =
0.002).
Clinical disease-free survival
Two RCTs of 1,258 PCa patients evaluated cDFS rates in
this meta-analysis. Significant heterogeneity was de-
tected between the two studies (P = 0.09, I2 = 65%), and
so, a random-effects model was applied. No significant
difference was observed with respect to cDFS between
the two groups (OR = 0.96, 95% CI: 0.22 to 4.18, P =
0.95; Figure 6).
Discussion
Two meta-analyses have assessed the use of neo-
adjuvant therapy for localized PCa [23,24], but the trialFigure 4 Meta-analysis of disease-free survival compared neo-adjuvanidentification criteria and primary endpoints in these
articles are different from ours. Our research demon-
strated a sufficient assessment of the clinical outcomes
in the neo-adjuvant therapy group compared with the
traditional therapy group, in patients with non-metastatic
PCa.
Although the number of relevant studies was not
enough to provide a reliable scientific basis, the clinical
outcomes presented herein strengthen the role of NHT
combined with RT or RP for non-metastatic PCa.Primary disclosures
The results from the statistical analyses demonstrated
that OS, PSM, and bDFS rates were significantly im-
proved in the neo-adjuvant therapy group. These posi-
tive results suggested that NHT could considerably
improve pathological outcomes and biochemical recur-
rence indicators such as PSM rate and serum PSA level.
This shows that these treatment outcomes, which in-
clude pathological and biochemical indicators, are effect-
ive alternatives for efficacy evaluation. However, there
was no significant difference in DFS and cDFS rates be-
tween the two groups in this systematic review. Consid-
ering the prognostic factors for systemic progression,
Stewart et al. [25] found that the Gleason grading sys-
tem indicates the risk of systemic progression in patients
treated with prostatectomy after NHT.t therapy group versus traditional therapy group.
Figure 5 Meta-analysis of biochemical disease-free survival compared neo-adjuvant therapy group versus traditional therapy group.
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heterogeneity between most individual studies. In our
opinion, the heterogeneity may be attributable to the fol-
lowing factors: different types and doses of drugs, devi-
ation in hormone allocation, definitions of biochemical
recurrence, and variations in patient characteristics and
follow-up duration. For instance, Laverdiere et al. [13]
defined biochemical recurrence as two consecutive in-
creases in serum PSA level of at least 1.0 and ≥1.5 ng/
ml, according to the Vancouver rules. In contrast, Den-
ham et al. [15] used the Houston method, which defines
biochemical failure as increases in PSA level of 2 ng/ml
or more above the post-treatment nadir measure.
This meta-analysis demonstrated that neo-adjuvant
therapy plus RP or RT was associated with longer OS
compared with RP or RT alone, in the overall combin-
ation therapy group as well as in each combination
treatment subgroup. Furthermore, the benefits of neo-
adjuvant therapy plus RP or RT included a significant
enhancement of loco-regional control in patients with
non-metastatic, intermediate- to high-risk PCa.
The disaggregated analysis of different risk groups in-
dicated that the superiority of neo-adjuvant therapy was
most manifest in patients with high-risk PCa. However,
the clinical significance of these outcomes is restricted
by the use of different risk categories among the studies.
The reliability of our preliminary findings will be verified
by the results of further targeted studies in this specific
area.Risk of bias evaluation
Since about half of the researches had not offered suffi-
cient evidence to verify whether the risk of bias in the
trial identification criteria and randomization measuresFigure 6 Meta-analysis of clinical disease-free survival compared neowas low or high, the quality of evidence analyzed in this
review varied.
Furthermore, it was unclear whether the outcome in-
spectors had been blinded to the group information in
all the studies, and some authors failed to report all
meaningful results, so the outcomes may be subject to
reporting bias, with missing information potentially lead-
ing to an overvaluation of the observed effects.
Limitations and prospects
The survival analyses presented in the published articles
tended to support NHT in combination with RP or RT.
However, many uncertainties still exist. Although OS
was obviously improved in these trials, which is a tan-
gible clinical outcome and an apparent superiority of the
regimen, the value of prolonged bDFS remains uncertain
and may not translate into certain survival benefit.
Owing to a ‘duration of risk’ effect, it seemed that PCa
patients must survive for more than 7 years to benefit
from the combined treatment. All the RCTs included in
this meta-analysis were from Western countries rather
than Asia. Thus, whether these outcomes can be extrap-
olated to Asian patients must be verified by further
research.
Therapeutic benefit and side effects should be bal-
anced by evidence-based adoption of the current infor-
mation. The various indicators that need to be noted
include PCa grade, risk group division, sexuality, life ex-
pectancy, physical function, and endocrine/metabolic
status (including hypertension, adiposity, and diabetes
mellitus).
Luteinizing hormone-releasing hormone agonist (LHRHa)
analogues were applied in most neo-adjuvant setting
trials, and the role of peripheral anti-androgens is still
unclear. Newly developed drugs acting through androgen-adjuvant therapy group versus traditional therapy group.
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play an important role in the future. Similarly, these
drugs are considered to offer more effective androgen
deprivation against prostate tumor cells, but whether
they can lead to an obvious therapeutic benefit, such as
tumor growth control and/or toxicity reduction, re-
quires further comprehensive and systematic research.
A recently published RCT [26] illustrated that LHRHa
plus abiraterone acetate (AA) treatment could suppress
tissue androgens more effectively than LHRHa alone.
Thus, intensive intratumoral androgen suppression with
LHRHa plus AA before RP may reduce tumor burden in
patients with localized high-risk PCa.
In addition, the above agents should be assessed with
regard to quality of life, adverse effects, and medical bur-
den to the patients, these parameters could not be sub-
jected to correlation analysis in this review. Physicians
should make reasonable treatment strategies for PCa pa-
tients according to the patients’ physical conditions,
financial capacities, and personal wishes.
Conclusions
The outcomes of this meta-analysis indicated that pa-
tients with intermediate- to high-risk PCa would benefit
more from NHT plus RT/RP than from RT/RP alone, al-
though several limitations need to be addressed due to
the small number of studies included.
Adverse reactions, medical costs during NHT, and
other objective limitations will affect the treatment
process significantly. Thus, physicians have to consider
all these issues when formulating individualized treat-
ment strategies.
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